Immunotherapy is a promising area of therapy in patients with neuro-oncological malignancies. However, earlyphase studies show unique challenges associated with the assessment of radiological changes in response to immunotherapy refl ecting delayed responses or therapy-induced infl ammation. Clinical benefi t, including long-term survival and tumour regression, can still occur after initial disease progression or after the appearance of new lesions. Refi nement of the response assessment criteria for patients with neuro-oncological malignancies undergoing immunotherapy is therefore warranted. Herein, a multinational and multidisciplinary panel of neuro-oncology immunotherapy experts describe immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria based on guidance for the determination of tumour progression outlined by the immune-related response criteria and the RANO working group. Among patients who demonstrate imaging fi ndings meeting RANO criteria for progressive disease within 6 months of initiating immunotherapy, including the development of new lesions, confi rmation of radiographic progression on follow-up imaging is recommended provided that the patient is not signifi cantly worse clinically. The proposed criteria also include guidelines for the use of corticosteroids. We review the role of advanced imaging techniques and the role of measurement of clinical benefi t endpoints including neurological and immunological functions. The iRANO guidelines put forth in this Review will evolve successively to improve their usefulness as further experience from immunotherapy trials in neuro-oncology accumulate.
Introduction
Immunotherapy for cancer has made exciting progress. The US Food and Drug Administration approved the fi rst vaccine against non-viral cancers (sipuleucel-T) 1 and blocking monoclonal antibodies to the immune checkpoint molecules CTLA-4 (ipilimumab) and PD-1 (pembroluzimab and nivolumab) for metastatic melanoma and non-smallcell lung cancer. [2] [3] [4] [5] Chimeric antigen receptor-engineered autologous T cells have induced durable remissions in patients with leukaemia refractory to conventional therapies, including bone marrow transplantation. 6, 7 For patients with primary and metastatic neuro-oncological malignancies, clinical trials assessing various immunotherapeutic approaches are underway, and promising preliminary results are emerging. [8] [9] [10] Ongoing evolution of response assessment in neuro-oncology Traditional imaging response assessment methods, including WHO criteria, 11 Response Evaluation in Solid Tumors (RECIST), 12 and Macdonald criteria, 13 originated in the cytotoxic therapy era when radiographic fi ndings directly represented anti-tumour eff ect. As oncology treatments have expanded beyond cytotoxic therapy, the eff ect of therapeutics on tumour imaging fi ndings has become less straightforward. For neuro-oncology, pseudoprogression after radiotherapy and temozolomide chemotherapy, 14 and pseudoresponse after antiangiogenic drugs, 15 underline challenges with the interpretation of imaging changes in the modern era. The Report Assessment for Neuro-Oncology (RANO) criteria 16 were proposed in 2010 to improve assessment of the evolving complexities of imaging for patients with malignant glioma. Subsequently, variations of the RANO criteria were refi ned for patients with low-grade glioma 17 and brain metastases. 18 A key cornerstone of the RANO criteria is guidance for the occurrence of pseudoprogression, which occurs in about 10-20% of newly diagnosed patients with glioblastoma after radiotherapy and temozolomide chemotherapy. 14, [19] [20] [21] The precise mechanism of pseudoprogression is still poorly understood, but most cases peak within 3 months of chemoradiation completion, although longer time periods have been reported. 19 Thereafter, radiographic changes might stabilise and ultimately improve. RANO guidelines have been widely used in daily practice and clinical research. Specifi cally, RANO criteria state that progressive disease should be diagnosed radiographically no sooner than 3 months after completion of concomitant radiotherapy and temozolomide chemotherapy, unless new enhancement outside the main radiation fi eld occurs or unequivocal tumour progression has been pathologically confi rmed. Furthermore, RANO criteria permit patients with progressive radiographic fi ndings of unclear aetiology to continue therapy pending follow-up imaging.
Important issues regarding progressive imaging fi ndings in patients with neuro-oncological malignancies treated with immunotherapy suggest that further adaptation of RANO criteria is warranted. First, the mechanism underlying pseudoprogression after immunotherapy is probably distinct from the mechanism associated with radiotherapy and temozolomide chemotherapy, with important diff erences in kinetics, frequency, and overall eff ect for patients. For example, although the temporal window for pseudoprogression after radiotherapy and temozolomide generally peaks within 3 months, the timeframe for immunotherapyassociated pseudo progression remains to be defi ned and might diff er by the class of immunotherapy given. Second, RANO criteria do not permit treatment continuation beyond actual tumour progression because subsequent therapeutic benefi t supporting this practice has not been documented for oncology treatments other than immunotherapies. Third, the appearance of a new lesion outside the main radiation fi eld automatically defi nes progressive disease by RANO criteria.
Interpretation of worsened radiographic fi ndings after immunotherapy
The interpretation of decreased size of an enhancing lesion is straightforward as such changes indicate a true anti-tumour eff ect because immunotherapeutics are not associated with pseudoresponse. By contrast, correct interpretation of progressive imaging fi ndings after administration of immunotherapy is essential because early progressive radiographic changes do not always preclude subsequent therapeutic benefi t. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Two main explanations exist for a possible disconnect between early worsened imaging fi ndings and subsequent therapeutic benefi t. First, eff ective immune responses might need time to evolve, and early imaging might refl ect true progressive disease, including the development of new lesions. Nonetheless, once induced, an eff ective antitumour immune response might subsequently lead to clinical benefi t. Second, because the mode of action might include an infl ammatory response in areas of macroscopic and microscopic infi ltrative tumour, localised infl ammatory responses might mimic radiological features of tumour progression with increased enhancement and oedema. 33 In an evaluation 22 of 487 patients with advanced melanoma treated with ipilimumab in three phase 2 studies, four patterns of radiographic response were observed. Two of these response patterns were captured by conventional WHO or RECIST criteria including radiologic response in baseline lesions with no new lesions and stable disease, which was followed by slow progressive decrease in tumour burden in some patients. Two other previously unrecognised patterns of response were not captured by conventional response assessment criteria. In some patients, an increase in size of existing lesions was followed by radiographic response or stable disease without the addition of further therapy other than ipilimumab. In other patients, new lesions were noted early on, but subsequent response or stable disease was later achieved without alternative therapeutic intervention.
Additional examples also emphasise the potential for early imaging worsening to be misleading in patients undergoing immunotherapy. First, spider plots that assess the percentage change in target lesion size from baseline over time for individual patients treated with anti-PD-1/PD-L1 therapy show enlargement of the initial tumour or even new lesions in some patients with melanoma before eventual decrease in tumour size. 26, 28, 31 Second, in an assessment 22 of 227 patients treated with ipilimumab, 22 (10%) patients who met WHO imaging criteria for progressive disease subsequently showed clinical benefi t, including fi ve patients who ultimately achieved partial response, and 17 patients who achieved stable disease. In a phase 2 study 34 of tremelimumab, another anti-CTLA-4 monoclonal antibody, eight patients showed a partial response of target lesions as measured by RECIST criteria concurrent with new lesions in six of the eight patients and progression of non-target lesions in two of the other patients. Of note, overall survival of these eight patients ranged from 21 to 39 months, whereas the median survival for all enrolled patients was 10·0 months. These examples underscore a potential disparity between early worsening on imaging assessment and ultimate clinical benefi t including improved survival in patients treated with immunotherapy.
The frequency of ultimate clinical benefi t after early progressive imaging fi ndings in patients with neurooncology malignancies undergoing immunotherapy is unknown. Preliminary results of initiated clinical trials assessing immune checkpoint blocking antibodies in patients with recurrent glioblastoma (NCT02054806 and NCT02017717) and vaccines in patients with WHO grade 2 low-grade glioma (NCT01678352) show that early progressive radiographic changes (fi gure 1) or appearance of new enhancing lesions (fi gure 2) might subsequently stabilise or disappear.
New lesions
Appearance of new lesions is a criterion that defi nes progression of disease by RANO criteria and the Macdonald criteria. However, transient appearance of new enhancing lesions at either local or distant sites might occur in patients with neuro-oncological malignancies receiving immunotherapy (fi gure 2). 25, 36 For cases of pseudoprogression, histopathology typically shows remarkable immune-cell infi ltration, such as CD8+ T lymphocytes, but not mitotically active tumour cells. 25 In such situations, careful radiological and clinical assessments are warranted. In some cases, new enhancing lesions might represent immune responses directed against infi ltrative brain tumour cells.
Confi rmation of radiographic progression to defi ne progressive disease
The immune-related response criteria were issued to aid the interpretation of imaging changes in patients with cancer undergoing immunotherapy. 22, 24, 37 Their intent was to raise awareness that traditional imaging criteria to defi ne progressive disease might be less reliable and could lead to premature discontinuation of potentially benefi cial therapy. A key component is the concept of confi rmation of radiographic progression. Review increases in lesion size or new lesions do not defi ne progressive disease unless further progressive changes are confi rmed upon follow-up imaging, provided that patients do not have a clinical decline. Confi rmation to defi ne progressive disease is an important, novel aspect of immune-related response criteria, although the converse argument, the need of follow-up imaging to confi rm a radiographic response, has been an accepted component of most response assessment metrics including RANO. Particularly for indications such as glioblastoma, for which few eff ective therapeutic interventions exist and for which durable responses are elusive, continuation of immunotherapies beyond initial progression might lessen the likelihood of prematurely discontinuing potentially eff ective therapy. 2, 22, 24 When is confi rmation of radiographic progression appropriate?
A crucial issue is identifi cation of patients who develop early progressive imaging fi ndings but still derive therapeutic benefi t from immunotherapy from those patients who are truly resistant to therapy and unlikely to benefi t clinically from immunotherapy. According to most response assessment criteria, including RANO, patients with substantial neurological decline, irrespective of imaging fi ndings, are deemed to have progressive disease, provided that their decline is not attributable to comorbid events such as seizures or changes in medication, notably a decreased corticosteroid dosing. For such patients, radiographic confi rmation of progressive disease is neither necessary nor appropriate and the date the patient's disease progressed is the date the patient developed substantial neurological decline attributable to their underlying tumour.
Future studies need to defi ne the time window for patients without neurological decline where early progressive imaging fi ndings do not preclude subsequent clinical benefi t. Studies 2, 26, 28, 31 show that most patients with solid tumours who benefi ted from immune checkpoint blockade antibodies have stable or improved radiographic fi ndings within 6 months of starting therapy, including those who have early progressive radiographic fi ndings. The kinetics of pseudoprogression or delayed response after various types of immunotherapy in patients with neuro-oncological malignancies needs prospective assessment. Nonetheless, anecdotal reports of patients with glioma treated with tumour vaccination therapy have described pseudoprogressive radiographic fi ndings that typically manifest within 6 months of starting treatment. 25, 36, 38 Conversely, no evidence exists that patients develop a delayed clinical benefi t or radiographic response if they 35 Although progressive fi ndings were noted at week 7, imaging at week 13 revealed stable disease. Clinically, the patient remained stable and corticosteroid dosing remained stable at 2 mg once a day. FLAIR=fl uid-attenuated inversion recovery.
Review develop progressive radiographic fi ndings more than 6 months after starting immunotherapy. To determine whether a 6-month window is appropriate to recommend confi rmation of radiographic progression, the immunotherapy Response Assessment for Neuro-Oncology (iRANO) working committee advocates that the pseudoprogression timeframe should be prospectively assessed in future immunotherapy trials.
3-month period to confi rm radiographic progression
Another crucial unanswered question regarding the signifi cance of early progressive imaging fi ndings is how long such changes can evolve before clinicians can confi dently conclude that they indicate true underlying tumour progression. Is there a period of time in which imaging fi ndings might continue to worsen but a patient might still derive clinical benefi t? Alternatively, how long should progressive imaging continue after starting immunotherapy to confi dently conclude that ultimate clinical benefi t is unlikely?
The immune-related response criteria guidelines recommend confi rmation of progressive disease with follow-up imaging at least 4 weeks from the initial scan documenting progressive disease. 22 Yet, 4 weeks might be too early to accurately ascertain the cause of early progressive imaging changes and conclude that eventual clinical benefi t is unlikely. In fact, spider plots describing changes in tumour volume over time for patients with solid tumours undergoing immune checkpoint blockade therapy show that early progressive radiographic fi ndings typically stabilise or improve within 3 months for most patients who ultimately derive clinical benefi t. 26, 28, 31 Similarly, a 3-month window has been defi ned by the RANO criteria to establish the cause of progressive imaging changes in patients with malignant glioma after radiotherapy and temozolomide chemotherapy. 14, 39 On the basis of these observations, the iRANO working committee recommends that for patients with early progressive imaging fi ndings, including patients who develop new lesions but who do not have substantial neurological decline, confi rmation of radiographic progression by follow-up imaging should be sought 3 months after initial radiographic evidence of progressive disease to decrease the likelihood of prematurely declaring progressive disease in patients with pseudoprogression or delayed response. Imaging Review within the 3-month follow-up can be done as medically appropriate at the discretion of the treating clinician.
In such patients, those with confi rmation of further radiographic progression based on a comparison with the scan that fi rst showed evidence of disease progression, or who develop substantial clinical decline at any time, should be classifi ed as having progressive disease with the date of disease progression back-dated to the fi rst date that the patient met criteria for radiographic progression. For these patients, immunotherapy should be discontinued. In the event that follow-up imaging does not confi rm further disease progression compared with the scan of the tumour that fi rst showed initial progressive changes, but instead there is stabilisation or reduction in tumour burden, treatment should be continued or resumed in the absence of increased corticosteroid dosing. We used a treatment algorithm to summarise guidance for follow-up imaging after initial progressive changes (fi gure 3).
Tissue acquisition to aid response assessment
In uncertain cases in which acquisition of tumour histopathology by biopsy or resection is thought to be feasible, pathological assessment might be considered to clarify the cause of progressive imaging fi ndings. If pathology confi rms a predominance of recurrent tumour, the cause should be considered to be true progression. For cases where there is no evidence of a viable tumour, or where a prominence of gliosis or infl ammation with restricted viable tumour is reported, the cause should be deemed consistent with treatment eff ect, and such patients should be classifi ed as stable and allowed to continue therapy.
Although thought to be the gold standard, interpretation of tumour tissue might be challenging. Biopsies typically acquire very small tissue aliquots and thus might be subject to sampling artifact. Additionally, many specimens will show mixed fi ndings, indicating the presence of viable tumour and treatment eff ect (infl ammation, necrosis, etc) and guidance on appropriate interpretation of such specimens is not yet available. Neuropathologists and neuro-oncologists should prospectively prioritise the careful assessment of histopathological samples obtained from patients undergoing immunotherapy to improve their understanding of the signifi cance of various patterns of mixed tissue fi ndings.
Immunotherapy continuation pending confi rmation of progression
Whether continued immunotherapy after initial disease progression would provide treatment effi cacy or harm to patients has not yet been established and further study of this important question is warranted. A decision of whether a patient should continue immunotherapy pending confi rmation of radiographic disease progression should be established based on perceived benefi ts and risks. Continuation of immunotherapy might be considered pending follow-up imaging as long as patients are deriving apparent clinical benefi t with minimal and acceptable toxic eff ects. By contrast, clinicians might consider interrupting immunotherapy for patients who need a substantial increase in corticosteroids (ie, >4 mg of dexamethasone or equivalent per day) for evolving symptoms associated with cerebral oedema or who have more than mild treatment-related toxic eff ects such as at least grade 2 immune-related adverse events.
Although somewhat arbitrarily set and not based on defi nitive data, these guidelines are included to limit the likelihood of progressive immunotherapy-induced infl ammatory changes leading to substantial defi cits in otherwise stable or symptom-free patients. In such patients, an interruption of immunotherapy dosing might be considered pending follow-up imaging. Furthermore, one might choose to discontinue or interrupt immunotherapy at any time if this option seems to be in the best medical interest of the patient. As a general guidance, resumption of immunotherapy might Review be taken into account when systemic dexamethasone is decreased to 4 mg/day or less and the gadoliniumenhancing tumour burden is classifi ed as stable disease, partial response, or complete response on a follow-up scan, or when relevant treatment-related toxic eff ects have resolved to grade 1 or less or pre-treatment baseline.
iRANO criteria
The iRANO guidelines incorporate criteria previously defi ned by the RANO working committee to defi ne complete response, partial response, minor response, stable disease, progressive disease, and non-evaluable disease for patients with malignant glioma, 16 low-grade glioma, 40 and brain metastases. 18 The key component of the iRANO criteria is specifi c additional guidance for the determination of progressive disease in patients with neuro-oncological malignancies undergoing immunotherapy (table 1, fi gure 3). Specifi cally, the iRANO criteria advocate for the confi rmation of radiographic progression in appropriate patients defi ned by clinical status and time from initiation of immunotherapy.
In patients who have imaging fi ndings that meet RANO criteria for progressive disease [16] [17] [18] within 6 months of starting immunotherapy including the development of new lesions, confi rmation of radiographic progression on follow-up imaging before defi ning the patient as nonresponsive to treatment might be needed provided that the patient does not have new or substantially worse neurological defi cits. Such patients might be allowed a window of 3 months before confi rming disease progression with the scan that fi rst showed initial progressive changes as the new reference scan for comparison with subsequent imaging studies. If RANO criteria for progressive disease are met on the follow-up scan 3 months later, non-responsiveness to treatment should be assumed, and the date of progressive disease should be back-dated to the initial date when it was fi rst identifi ed (table 1) . Patients who develop substantial new or worsened neurological defi cits not due to comorbid events or a change in co-administered medication at any time within the 3-month follow-up window should be designated as non-responsive to treatment and should discontinue immunotherapy. For these patients, the date of actual tumour progression should also be back-dated to the date when radiographic progressive disease was initially identifi ed.
If radiographic fi ndings at the 3-month follow-up meet RANO criteria for stable disease, partial response, or complete response [16] [17] [18] compared with the original scan meeting criteria for progression, and no new or worsened neurological defi cits are identifi ed, such patients should be deemed as deriving clinical benefi t from therapy and allowed to continue treatment. Patients who develop worsening radiographic fi ndings compared with the pretreatment baseline scan more than 6 months from starting immunotherapy are expected to have a low likelihood of ultimately deriving clinical benefi t and should be regarded as non-responsive to treatment with a recommendation to discontinue therapy.
Overall, we have integrated guidance from the immunerelated response criteria regarding interpretation of progressive imaging fi ndings with existing RANO criteria to form the iRANO guidelines. A comparison of the key features associated with RANO, immune-related response Malignant glioma 16 Low-grade glioma 17 Brain metastases 18 Complete response The iRANO criteria integrate into the existing RANO criteria for malignant glioma, low-grade glioma, and brain metastases by providing recommendations for the interpretation of progressive imaging changes. Specifi cally, iRANO recommends confi rmation of disease progression on follow-up imaging 3 months after initial radiographic progression if there is no new or substantially worsened neurological defi cits that are not due to comorbid events or concurrent medication, and it is 6 months or less from starting immunotherapy. If follow-up imaging confi rms disease progression, the date of actual progression should be back-dated to the date of initial radiographic progression. The appearance of new lesions 6 months or less from the initiatiation of immunotherapy alone does not defi ne progressive disease. FLAIR=fl uidattenuated inversion recovery. iRANO=immunotherapy Response Assessment in Neuro-Oncology. N/A=not applicable. Review criteria, and iRANO are summarised (table 2) . Although application of immuno therapies for patients with neurooncological malignancies is in the early stages of development and much remains to be learned, the iRANO criteria provides guidelines that can be applied to provide consistent metrics in clinical trials and daily practice. Particularly, these guidelines shall raise awareness of the possibility of potentially misleading early progressive radiographic changes after initiation of immunotherapy, and provide guidance for responding to these changes to decrease the likelihood of inappropriate premature therapy discontinuation. We expect the iRANO guidelines will be amended successively to improve their usefulness as further experience and systematic data from continuing immunotherapy trials in neuro-oncology accumulate.
Corticosteroids
Patients with brain tumours frequently develop peritumoral oedema needing treatment with corticosteroids. Dexamethasone is the most commonly used corticosteroid. 41, 42 In addition to the systemic side-eff ects, dexamethasone can have profound eff ects on contrast enhancement for neuroimaging studies and on the immune system, especially T cells. 43 In preclinical studies, administration of dexamethasone to rats with intracranial C6 glioblastomas dose-dependently decreased intratumoral infi ltration by lymphocytes and microglial cells, 44 and limited cytokine-mediated anti-tumour eff ects and survival of rats bearing 9L gliomas. 45 Several clinical studies have shown that dexamethasone can inhibit maturation of dendritic cells and subsequently their potential for antigen presentation. 46, 47 In patients with cancer receiving immunotherapy, dexamethasone can also impair natural-killer-cell activity. 48 In patients with glioblastoma, treatment with dexamethasone favours the emergence of a population of CD14+ HLA-DR low/-monocytes that inhibit T-cell proliferation. 49 Most of the data for the eff ect of corticosteroids on immune system activity derive from the assessment of high dosing schedules. By contrast, minimal data exist for the eff ects of diff erential doses, 50, 51 whereas the long-term eff ects of low-to-moderate dexamethasone doses on immune-cell function remain unclear. Nonetheless, in view of its potential negative eff ects on dendritic cell, T-cell, and natural-killer-cell function, dexamethasone doses and duration of therapy should be limited to the minimum amount needed to control neurologic symptoms.
As a general guideline, patients enrolling in immunotherapy trials should have as little dexamethasone as possible before starting treatment. If pseudoprogression occurs during the course of treatment, higher doses of corticosteroids might be necessary to control symptoms. Although this might potentially reduce immunotherapy effi cacy, available data are inconclusive. In a trial assessing the effi cacy of ipilimumab for patients with melanoma who have brain metastases, patients who needed corticosteroids during study therapy had a worse outcome. 52 Although this could be due to the negative eff ect of the corticosteroids on immune function, the group needing corticosteroids could have had larger tumours and worse prognostic factors than the group who did not need corticosteroids.
Of note, patients who need increased corticosteroid use within 2 weeks of MRI assessment relative to the dose taken at the time of the previous assessment, cannot be classifi ed as having a complete response, partial response, or stable disease and should be classifi ed as non-evaluable at that timepoint. Conversely, patients who decrease corticosteroid use within 2 weeks of MRI assessment relative to the dose taken at the time of the previous assessment cannot be classifi ed as having progressive disease and should be classifi ed as nonevaluable. Recent advances in imaging techniques and measurement of clinical benefi t endpoints including neurological and immunological functions are shown in the appendix.
Conclusion
We propose updated response assessment criteria for the assessment of patients with neuro-oncological malignancies undergoing immunotherapy. These recommendations integrate the framework of response assessment established by the RANO working group for malignant glioma, 16 low-grade glioma, 40 and brain metastases 18 with guidance for confi rmation of disease progression as originally advocated by the immunerelated response criteria to guide clinical decision making. The iRANO guidelines specifi cally address interpretation Review of initial progressive imaging fi ndings in the context of patients with neuro-oncological malignancies with a goal of decreasing the likelihood of premature discontinuation of potentially benefi cial therapies while ensuring maximum patient safety. The iRANO guidelines will inevitably need future amendment, including possible incorporation of advanced imaging techniques, once suffi cient experience and expertise are acquired for each of the major classes of immune-based therapies in patients with neuro-oncological malignancies. Prospective assessment of the iRANO criteria in clinical trials for patients with brain tumours undergoing immunotherapy trials will be needed to confi rm their ultimate clinical usefulness.
